Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
对于不适合自体干细胞移植的新诊断多发性骨髓瘤患者，采用伊沙佐米-沙利度胺-低剂量地塞米松诱导治疗，随后进行伊沙佐米或安慰剂维持治疗；来自随机II期HOVON-126/NMSG 21.13试验的结果
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2019.240374
Zweegman, Sonja; Stege, Claudia A M; Haukas, Einar; Schjesvold, Fredrik H; Levin, Mark-David; Waage, Anders; Leys, Rineke B L; Klein, Saskia K; Szatkowski, Damian; Axelsson, Per; Hieu Do, Trung; Knut-Bojanowska, Dorota; van der Spek, Ellen; Svirskaite, Asta; Klostergaard, Anja; Salomo, Morten; Blimark, Celine; Ypma, Paula F; Mellqvist, Ulf-Henrik; Poddighe, Pino J; Stevens-Kroef, Marian; van de Donk, Niels W C J; Sonneveld, Pieter; Hansson, Markus; van der Holt, Bronno; Abildgaard, Niels
发育与干细胞
干细胞
多发性骨髓瘤
多发性硬化症
骨髓瘤
细胞生物学
